CAR T cells better than BiTEs.
作者信息
Molina John C, Shah Nirali N
机构信息
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD; and.
Department of Pediatric Oncology, Johns Hopkins Hospital, Baltimore, MD.
出版信息
Blood Adv. 2021 Jan 26;5(2):602-606. doi: 10.1182/bloodadvances.2020003554.
Abstract
摘要
相似文献
1
CAR T cells better than BiTEs.嵌合抗原受体T细胞比双特异性T细胞衔接器更好。
Blood Adv. 2021 Jan 26;5(2):602-606. doi: 10.1182/bloodadvances.2020003554.
2
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.制造用于过继性免疫治疗的嵌合抗原受体（CAR）T细胞。
J Vis Exp. 2019 Dec 17(154). doi: 10.3791/59949.
3
CAR T Cells.嵌合抗原受体 T 细胞。
Neurosurg Clin N Am. 2021 Apr;32(2):249-263. doi: 10.1016/j.nec.2020.12.005. Epub 2021 Feb 18.
4
Chimeric antigen receptor (CAR) T therapy and cognitive functions.嵌合抗原受体（CAR）T细胞疗法与认知功能。
J Neurol Sci. 2023 Jan 15;444:120495. doi: 10.1016/j.jns.2022.120495. Epub 2022 Nov 16.
5
[Structural evolution and prospect of chimeric antigen receptor T cell (CAR-T cell)].嵌合抗原受体T细胞（CAR-T细胞）的结构演变与展望
Zhonghua Xue Ye Xue Za Zhi. 2020 Nov 14;41(11):964-968. doi: 10.3760/cma.j.issn.0253-2727.2020.11.019.
6
Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.嵌合抗原受体 T 细胞疗法治疗癌症：以基础研究为导向的观点。
Immunotherapy. 2018 Mar;10(3):221-234. doi: 10.2217/imt-2017-0133.
7
[Cell therapy's poster child: Chimeric antigen receptor T cell therapy].[细胞疗法的典型代表：嵌合抗原受体T细胞疗法]
Sheng Wu Gong Cheng Xue Bao. 2019 Dec 25;35(12):2339-2349. doi: 10.13345/j.cjb.190291.
8
Advances and Challenges of CAR T Cells in Clinical Trials.嵌合抗原受体T细胞在临床试验中的进展与挑战
Recent Results Cancer Res. 2020;214:93-128. doi: 10.1007/978-3-030-23765-3_3.
9
The Evolving Protein Engineering in the Design of Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞设计中的不断发展的蛋白质工程。
Int J Mol Sci. 2019 Dec 27;21(1):204. doi: 10.3390/ijms21010204.
10
Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells.从T细胞载体到嵌合抗原受体免疫细胞，为最大化嵌合抗原受体T细胞疗法治疗癌症的潜力所做的努力。
Int J Hematol. 2021 Nov;114(5):529-531. doi: 10.1007/s12185-021-03213-8. Epub 2021 Sep 13.
引用本文的文献
1
Fragment-Based Immune Cell Engager Antibodies in Treatment of Cancer, Infectious and Autoimmune Diseases: Lessons and Insights from Clinical and Translational Studies.基于片段的免疫细胞衔接抗体在癌症、感染性疾病和自身免疫性疾病治疗中的应用：临床和转化研究的经验与见解
Antibodies (Basel). 2025 Jun 24;14(3):52. doi: 10.3390/antib14030052.
2
Insights from the bottom-up development of LGR5-targeting immunotherapeutics.靶向LGR5的免疫疗法自下而上开发的见解。
Immunother Adv. 2025 Apr 25;5(1):ltaf017. doi: 10.1093/immadv/ltaf017. eCollection 2025.
3
The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?嵌合抗原受体（CAR）T细胞疗法在儿科患者中的应用：我们从何而来，如今身处何方，又将走向何处？
Clin Hematol Int. 2024 Mar 13;6(1):96-115. doi: 10.46989/001c.94386. eCollection 2024.
4
A bispecific antibody that targets the membrane-proximal region of mesothelin and retains high anticancer activity in the presence of shed mesothelin.一种靶向间皮素膜近端区域且在存在脱落的间皮素时仍保留高抗癌活性的双特异性抗体。
Mol Cancer Ther. 2024 Apr 22. doi: 10.1158/1535-7163.MCT-23-0233.
5
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment.一种 CD3 人源化小鼠模型揭示了双特异性抗体治疗引起的 T 细胞反应的独特特征。
Blood Adv. 2024 Jan 23;8(2):470-481. doi: 10.1182/bloodadvances.2023010971.
6
FCRL1 immunoregulation in B cell development and malignancy.FCRL1 在 B 细胞发育和恶性肿瘤中的免疫调节作用。
Front Immunol. 2023 Sep 25;14:1251127. doi: 10.3389/fimmu.2023.1251127. eCollection 2023.
7
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.四十余年来，MD 安德森对急性淋巴细胞白血病的研究与治疗的进展
J Hematol Oncol. 2023 Mar 16;16(1):22. doi: 10.1186/s13045-023-01409-5.
8
Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer.双特异性T细胞衔接器疗法在实体瘤中的应用：聚焦前列腺癌
Cancers (Basel). 2023 Feb 23;15(5):1412. doi: 10.3390/cancers15051412.
9
Top advances of the year: Leukemia.年度重大进展：白血病。
Cancer. 2023 Apr 1;129(7):981-985. doi: 10.1002/cncr.34619. Epub 2022 Dec 30.
10
Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions.嵌合抗原受体 T 细胞疗法的心脏不良效应：特征、监测、管理和未来研究方向。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221132927. doi: 10.1177/15330338221132927.
本文引用的文献
1
Improving CAR T-cells: The next generation.提高 CAR T 细胞：下一代。
Semin Hematol. 2020 Jul;57(3):115-121. doi: 10.1053/j.seminhematol.2020.07.002. Epub 2020 Jul 23.
2
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma.替沙格赛定用于儿童急性淋巴细胞白血病和非霍奇金淋巴瘤的真实世界证据。
Blood Adv. 2020 Nov 10;4(21):5414-5424. doi: 10.1182/bloodadvances.2020003092.
3
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.双特异性抗 CD20、抗 CD19 CAR T 细胞治疗复发 B 细胞恶性肿瘤：1 期剂量递增和扩展试验。
Nat Med. 2020 Oct;26(10):1569-1575. doi: 10.1038/s41591-020-1081-3. Epub 2020 Oct 5.
4
CAR T cell therapies for patients with multiple myeloma.嵌合抗原受体 T 细胞疗法治疗多发性骨髓瘤患者。
Nat Rev Clin Oncol. 2021 Feb;18(2):71-84. doi: 10.1038/s41571-020-0427-6. Epub 2020 Sep 25.
5
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
6
Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma.自动化制造自体 CD19 CAR-T 细胞治疗非霍奇金淋巴瘤。
Front Immunol. 2020 Aug 7;11:1941. doi: 10.3389/fimmu.2020.01941. eCollection 2020.
7
Engineering CAR-T Cells for Next-Generation Cancer Therapy.工程化 CAR-T 细胞用于下一代癌症治疗。
Cancer Cell. 2020 Oct 12;38(4):473-488. doi: 10.1016/j.ccell.2020.07.005. Epub 2020 Jul 30.
8
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.抗CD19嵌合抗原受体T细胞疗法治疗110例具有高危特征的B细胞急性淋巴细胞白血病患者的疗效与安全性
Blood Adv. 2020 May 26;4(10):2325-2338. doi: 10.1182/bloodadvances.2020001466.
9
Recent Advances in Managing Acute Lymphoblastic Leukemia.急性淋巴细胞白血病治疗的最新进展。
Am Soc Clin Oncol Educ Book. 2020 May;40:330-342. doi: 10.1200/EDBK_280175.
10
Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.双特异性抗体治疗多发性骨髓瘤：靶点、药物、临床试验及未来方向的综述。
Front Immunol. 2020 Apr 24;11:501. doi: 10.3389/fimmu.2020.00501. eCollection 2020.
Zotero 插件